Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

147.75
+3.422.37%
Post-market: 142.39-5.3600-3.63%19:52 EDT
Volume:567.40K
Turnover:82.97M
Market Cap:9.56B
PE:143.45
High:149.30
Open:143.26
Low:141.95
Close:144.33
52wk High:160.81
52wk Low:54.50
Shares:64.71M
Float Shares:63.17M
Volume Ratio:1.20
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-2.0500
ROE:10.98%
ROA:4.55%
PB:11.36
PE(LYR):-72.07

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)

TIPRANKS
·
5 hours ago

Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says

MT Newswires Live
·
10 hours ago

Citigroup Raises Protagonist Therapeutics Price Target to $182 From $175, Buy Rating Kept

MT Newswires Live
·
10 hours ago

Protagonist Therapeutics price target raised to $170 from $165 at Citizens

TIPRANKS
·
11 hours ago

Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says

MT Newswires Live
·
Yesterday

Protagonist Therapeutics is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Yesterday

Protagonist Therapeutics (PTGX) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Yesterday

U.S. Research Roundup-Adobe, Braveheart Bio, CACI International

Reuters
·
Yesterday

Protagonist Therapeutics, Inc. : Jefferies Raises Target Price to $171 from $169

THOMSON REUTERS
·
Yesterday

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

TIPRANKS
·
Yesterday

Why Protagonist Therapeutics (PTGX) Is Down 6.5% After FDA Approval Triggers $275M Milestone Payment

Simply Wall St.
·
Aug 30

Protagonist Says FDA Approves Takeda’s Mimrylo for Polycythemia Vera Erythrocytosis

Reuters
·
Aug 29

US FDA Approves Takeda, Protagonist's Drug for Rare Blood Cancer

Reuters
·
Aug 29

Protagonist Therapeutics Grants Inducement Equity Awards for 7,175 Shares to New Hires at USD 155.1 Strike Price

Reuters
·
Aug 19

Protagonist Therapeutics is Maintained at Outperform by BMO Capital

Dow Jones
·
Aug 17

Protagonist Therapeutics price target raised to $178 from $112 at BMO Capital

TIPRANKS
·
Aug 17

Protagonist Therapeutics, Inc. : Bmo Raises Target Price to $178 from $112

THOMSON REUTERS
·
Aug 17

Protagonist Therapeutics (PTGX) Is Up 6.3% After Swing To Q2 Profitability And ESOP Usage Shift

Simply Wall St.
·
Aug 17

Protagonist Therapeutics CEO Dinesh V. Patel Disposes of USD 14.89 Million in Common Shares

Reuters
·
Aug 13

Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says

MT Newswires Live
·
Aug 11